| http://www.w3.org/ns/prov#value | - erse events (mainly gastrointestinal events including nausea, diarrhea and vomiting) were 33 (10.4%) in the lixisenatide group and 41 (13.0%) in the exenatide group Significantly fewer patients experienced symptomatic hypoglycemia with lixisenatide (2.5% vs. 7.9%, p < 0.05), with 6-fold fewer hypoglycemic events (8 vs. 48) versus exenatide More lixisenatide patients tolerated the target dose of 20
|
